Slides
Page 1
Camlin Fine Sciences Limited Investor Presentation – May 2025
Page 2
2 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.
Page 3
Performance Highlights – Q4 & FY25 3
Page 4
Margin from Core Business FY25 Operational Highlights On Consolidated Basis *EBITDA is adjusted for FX loss 4 • Total Revenue for FY25 improved by 15% to Rs. 16,665 mn on YoY basis • Adjusted EBITDA for FY25 improved by 13% to Rs. 2,081 mn on YoY basis • EBITDA margin stood at 12.5% for the core business in FY25 • Dominance in Blends continue with a total revenue of Rs. 8,784 mn as compared to last year of Rs. 7,474 mn, a growth of 18% on YoY basis • Healthy growth in Blends will continue in North America and Domestic market • CFS Vitafor contributed Rs. 849 mn to the total Blends revenue in the FY25 • Growth momentum continued from Aroma Ingredients with total contributions of Rs 1,758 mn for FY25. Revenue will ramp up further in the coming quarters • Right Issue of Rs. Rs. 2,247 mn was issued in Jan 25 • NCD of Rs. 1,000 million borrowed in Q3 FY25 was repaid in Q4 FY25 using rights issue proceeds • Net Debt stood at Rs. 4,918 million as of March 2025, down from Rs. 5,641 million in March 2024 • Net Debt-to-Equity ratio improved to 0.55x, from 0.65x in the previous year From Continuing Operations Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 1,591 263 14,539 16,665 FY24 FY25 16,131 16,928 1,836 2,081 -858 -507 FY24 FY25 978 1,574 530 494 -1,578 -2,075 FY24 FY25 -1,049 -1,581 12.63% -6.57% FY24 12.50% -3.19% FY25 6.06% 9.31% EBITDA Margin % Discontinued Operation Continued Operation
Page 5
Q4 & FY25 Performance Highlights Revenue (Rs. In Mn) EBITDA* (Rs. In Mn) PAT (Rs. In Mn) On Consolidated Basis *EBITDA is adjusted for FX loss 5 3,767 4,310 4,375 Q4FY24 Q3FY25 Q4FY25 492 622 594 Q4FY24 Q3FY25 Q4FY25 195 16 227 Q4FY24 Q3FY25 Q4FY25 % Margin13.6%14.4%13.1% 14,539 16,665 FY24 FY25 1,836 2,081 FY24 FY25 530 494 FY24 FY25 # FY24 and FY25 figures exclude Diphenol CFS Europe and entire CFSWL discontinued operations 12.5%12.6% From Continuing Operations#
Page 6
Operational Revenue Breakup Specialty Ingredients (Rs. In Mn) (Straights) Specialty Ingredients (Rs. In Mn) (Value added blends) Total Specialty Ingredients (Rs. In Mn) On Consolidated Basis Performance Chemicals (Rs. In Mn) Aroma Ingredients (Rs. In Mn) Total Revenue Breakup (%)* Specialty Ingredients (Straights) Specialty Ingredients (Value Added Blends) Performance Chemicals Aroma Ingredients 6 5% 15% 2% 11%18% 14% 17% 12% 50% 47% 52% 54% 27% 24% 29% 23% Q4FY24 Q4FY25 FY24 FY25 3,752 4,119 14,344 16,319 1,017 976 4,111 3,821 Q4FY24 Q4FY25 FY24 FY25 1,884 1,949 7,474 8,784 Q4FY24 Q4FY25 FY24 FY25 2,900 2,925 11,585 12,605 Q4FY24 Q4FY25 FY24 FY25 677 586 2,412 1,956 Q4FY24 Q4FY25 FY24 FY25 174 608 347 1,758 Q4FY24 Q4FY25 FY24 FY25 *Excluding Other Products #Historical numbers are restated / regrouped From Continuing Operations# # FY24 and FY25 figures exclude Diphenol CFS Europe and entire CFSWL discontinued operations
Page 7
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn) 7 2,203 2,726 7,733 8,865 Q4FY24 Q4FY25 FY24 FY25 1,217 1,178 4,822 5,062 Q4FY24 Q4FY25 FY24 FY25 162 126 679 525 Q4FY24 Q4FY25 FY24 FY25 361 433 1,504 1,571 Q4FY24 Q4FY25 FY24 FY25 619 953 2,552 3,596 Q4FY24 Q4FY25 FY24 FY25 159 849 Q4FY24 Q4FY25 FY24 FY25 0 0 CFS Vitafor (Rs. In Mn) From Continuing Operations# #Historical numbers are restated / regrouped# FY24 and FY25 figures exclude Diphenol CFS Europe and entire CFSWL discontinued operations
Page 8
Particulars (Rs. In Mn) Q4 FY25 Q4 FY24 YoY Q3 FY25 QoQ FY25 FY24 YoY Revenue from Operation 4,374.6 3,766.5 16.1% 4,310.2 1.5% 16,665.3 14,539.1 14.6% Raw material consumption 2,153.0 2,063.7 2,141.1 8,492.6 7,698.5 Employee Cost 501.3 398.4 479.2 1,922.9 1,525.3 Other expenses 1,126.3 989.7 1,112.4 4,168.6 3,718.2 EBITDA 594.1 314.8 88.7% 577.6 2,081.1 1,597.0 30.3% EBITDA Margins (%) 13.6% 8.4% 13.4% 12.5% 11.0% Adjusted EBITDA* 594.1 492.0 20.7% 621.6 -4.4% 2,081.1 1,836.0 13.3% Adjusted EBITDA Margins (%) 13.6% 13.1% 50 bps 14.4% - 80 bps 12.5% 12.6% 100 bps Other Income 95.9 57.5 13.4 144.5 155.5 Depreciation 183.9 133.7 144.8 638.4 563.5 Finance cost 161.1 161.2 340.7 998.8 603.0 Exceptional Item 55.9 0.0 0.0 98.2 0.0 Share of profit / loss of associate 17.9 0.0 -18.5 4.4 0.0 PBT 307.0 77.4 87.0 494.7 585.9 Tax 79.5 -117.2 71.4 0.7 56.3 PAT 227.4 194.6 16.9% 15.5 494.0 529.6 -6.7% PAT Margin (%) 5.2% 5.2% 0.4% 3.0% 3.6% Consolidated Profit & Loss Statement 8*EBITDA is adjusted for FX loss PBT from discontinued operation -226.3 -1,012.5 -90.2 -2,075.2 -1,578.4 Tax expense of discontinued operations 0.0 0.0 0.0 0.0 0.0 PAT including Discontinued Operations 1.1 -817.9 -74.7 -1,581.2 -1,048.8 From Discontinued Operations From Continuing Operations#
Page 9
Particulars (Rs. In Mn) Q4 FY25 Q4 FY24 YoY Q3 FY25 QoQ FY25 FY24 YoY Revenue from Operation 2,726.0 2,203.3 23.7% 2,050.7 32.9% 8,864.9 7,732.6 14.6% Raw material consumption 1,473.5 1,650.1 1,012.9 4,812.6 4,436.7 Employee Cost 188.9 165.4 171.8 724.8 659.5 Other expenses 730.9 644.2 702.0 2,621.5 2,365.2 EBITDA 332.7 -256.5 - 164.0 102.9% 706.0 271.3 160.2% EBITDA Margins (%) 12.2% -11.6% 8.0% 8.0% 3.5% Adjusted EBITDA* 338.2 -256.5 - 164.0 106.2% 706.0 271.3 160.2% Adjusted EBITDA Margins (%) 12.4% -11.6% 8.0% 440 bps 8.0% 3.5% 450 bps Other Income 89.4 55.5 68.2 206.2 188.8 Depreciation 131.3 127.8 132.6 525.3 493.9 Finance cost 174.4 138.8 171.5 661.2 543.3 Exceptional Item -2.6 19.3 0.0 960.0 19.3 Share of profit / loss of associate 0.0 0.0 0.0 0.0 0.0 PBT 119.0 -486.8 - -71.9 -1,234.3 -596.3 - Tax -37.2 -46.1 -15.7 -471.2 -82.4 PAT 156.2 -440.7 - -56.3 -763.1 -513.9 - Standalone Profit & Loss Statement 9*EBITDA is adjusted for FX loss Exceptional Items – FY25 i) Impairment loss on investments in subsidiaries namely: a. CFS Europe Rs. 118 mn , b. CFSWL Rs. 44 mn ( Previous year ended 31.03.2024 Rs. 19 mn) , c. CFS Pahang Asia Pte Ltd Rs. 1. 8 mn ii) Impairment of trade and other receivables (net of payables) due from subsidiaries: a. CFS Europe SpA Rs. 193 mn, b. CFSWL Rs. 594 mn iii) Loss on demolition / refurbishment of assets Rs. 9.6 mn
Page 10
Consolidated Balance Sheet 10 Particulars (Rs. In Mn) Mar – 25 Mar – 24 Equity Equity Share Capital 187.9 167.5 Other Equity 8,828.8 8,480.0 Minority interest -268.9 -78.0 Total Equity 8,747.8 8,569.5 Non-Current Liabilities Financial Liabilities Borrowings 2,683.0 3,327.2 Lease Liabilities 251.4 171.6 Other Liabilities 3.8 3.3 Provisions 54.8 51.1 Deferred Tax Liabilities (Net) 33.1 68.4 Other non-current liabilities 1.8 3.5 Total Non -Current Liabilities 3,028.0 3,625.5 Current Liabilities Financial Liabilities Borrowings 3,773.4 3,249.4 Lease Liabilities 105.2 82.1 Trade Payables 3,772.2 3,246.4 Other Financial Liabilities 518.9 319.3 Other Current Liabilities 159.4 327.8 Provisions 110.8 95.8 Current tax liabilities (Net) 22.1 1.9 Total Current Liabilities 8,462.1 7,322.7 Total Equity and Liabilities 20,237.9 19,517.2 Particulars (Rs. In Mn) Mar – 25 Mar - 24 Non-Current assets Property, Plant and Equipment 5,925.6 7,122.4 Capital Work -In-Progress 97.3 455.6 Right use of assets 513.5 445.2 Goodwill 474.7 470.8 Other Intangible Assets 102.3 125.1 Intangible assets under development 0.0 3.1 Investment Property 21.6 0.0 Financial Assets Investments 229.7 78.8 Other Financial Assets 144.0 138.8 Deferred tax assets 650.3 405.0 Income Tax Assets 187.3 211.8 Other Non-Current Assets 57.7 54.1 Total Non-Current Assets 8,404.0 9,510.6 Current Assets Inventories 5,268.6 5,127.0 Financial Assets Investments 380.1 0.0 Trade Receivables 3,282.2 2,851.5 Cash and Cash Equivalents 1,040.7 802.5 Bank Balances 497.3 132.8 Loans 100.0 100.6 Other Financial Assets 23.8 18.1 Other Current Assets 1,241.2 953.4 Assets held for sale 0.0 20.7 Total Current Assets 11,833.9 10,006.7 Total Assets 20,237.92 19,517.2
Page 11
Consolidated Cash Flow Statement 11 Particulars (Rs. In mn) Mar – 25 Mar – 24 Profit Before Tax Continuing operations 494.7 585.9 Discontinued operations (2,075.2) (1,578.4) Net Profit Before Tax (1,580.5) (992.4) Adjustments for: Non-Cash Items / Other Investment or Financial Items 3,013.6 2,540.9 Operating profit before working capital changes 1,433.1 1,548.4 Changes in working capital 784.2 (316.7) Cash generated from Operations 648.9 1,865.2 Direct taxes paid (net of refund) (381.7) (475.3) Net Cash from Operating Activities 267.2 1,389.8 Net Cash from Investing Activities (753.5) (665.0) Net Cash from Financing Activities 724.4 (859.7) Net Decrease in Cash and Cash equivalents 238.2 (134.9) Add: Cash & Cash equivalents at the beginning of the period 802.5 937.4 Cash & Cash equivalents at the end of the period 1,040.7 802.5
Page 12
Company Overview
Page 13
100+ Range of Diversified Products 1,250+ Base of Satisfied Customers Worldwide 49,000+ Led by Integrated Global Production Capacity Among Global Leaders in the Manufacturing of Antioxidants Preferred Partner For Customized Shelf-Life Solutions High Quality & Wide Range Vanillin Manufacturer *Breakup excludes revenue from Other Products FY25 Revenue Mix* ₹ 16,319 mn Food & Beverage Animal Nutrition Pet Food Flavours & Fragrances Dietary Supplements Pharmaceuticals & Pharma Intermediates Petrochemicals Dyes & Pigments Polymers Agrochemicals Rendering Bio-Fuels Aquaculture & Fishmeal Personal Care & Home Care Incense Sticks Catering Diverse Industries Company Overview 13 11% 12% 54% 23% Specialty Ingredients Value added Blends Performance Chemicals Aroma Ingredients # FY25 figures exclude Diphenol CFS Europe and entire CFSWL discontinued operations
Page 14
Specialty Ingredients Value – added Blends Performance Chemicals Aroma Ingredients › TBHQ › BHA › Ascorbyl palmitate (ASP) › 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends) › HQ derivatives products like Chloranil, MEHQ, HQEE, TBHQ, PDMB, CME, › CT derivative products like 4 TBC, Guethol, Veratrole, Guaiacol, 1, 2MDB › Vanillin, Ethyl Vanillin and Vanillin ex- clove (adorr ) › Pet Food › Livestock Nutrition › Food & Beverages › Fish Meal › Animal Feed Mills › Biodiesel › Aquaculture & Fishmeal › Rendering › Petrochemicals › Dyes & Pigments › Agrochemicals › Polymers › Pharmaceuticals › Acrylates › Electroplating › Printing Inks › Food & Beverages › Pharmaceutical › Incense sticks › Animal Feed › Flavors & Fragrance › Agrochemicals › Personal Care Key Products End User Industries Key Brands › These formulations are specifically tailored to meet the diverse needs of the industry › Aim to increase focus on high-value blends and additives FY25 Sales Mix%* 23% 54% 12% Straights 11% Product Highlights 14 *Breakup excludes revenue from Other Products # FY25 figures exclude Diphenol CFS Europe and entire CFSWL discontinued operations
Page 15
Innovation at Work Powered by Vertical Integration • High-Quality Hydroquinone : Developing a high-quality specialized grade for Hydroquinone, leading to the crucial phase of conducting plant trials • Antioxidant Innovations : Successfully developed and implemented enhanced quality of antioxidants, tailored specifically for discerning customers . These products have smoothly transitioned from R&D to full scale production and have already made market debut • Naturals & Emulsifiers : Newest offerings include emulsifier -based ingredients designed to enhance texture, consistency, mouthfeel, appearance, process efficiency and yield for diverse range of food industry applications • Upcoming Products : FY26 will see the commercialization of many new products, which includes products in Dyes & Pigments and Agrochemicals . • Efforts in both organic and inorganic expansions, showcases company’s commitment to fortifying position in the market • Strategic focus on captive consumption ensures utilization of raw materials for downstream products • Strategic forward integration into Blends and Vanillin swings company's business model to high-value additives / solutions Product Development : Process Optimization Initiatives • Vanillin Production Optimization : Continuous improvement at our new Dahej plant, refining processes and setting a future – oriented strategic direction • HQ Derivatives Process : Developed a novel, process with improved selectivity for producing HQ derivatives from alternate routes . This initiative is presently being evaluated and is a promising step to enhance our capabilities • Dyes & Pigments : R&D efforts have paved way for new processes tailored for dyes and pigment industry, including a pioneering zero liquid discharge process that effectively addresses critical impurity challenges • Animal Nutrition : Dedicated to the continuous improvement and development of products using technical expertise of CS Dresen and customizing products to suit the market needs, anticipated for the upcoming year • Quality Enhancements : Focused on Analytical and Quality Enhancements through Instrumental Analysis and Method Development, which play critical roles in ensuring the integrity and efficacy of our products 15
Page 16
Acquisition of Vitafor Invest NV • Leveraging Vitafor’s network to augment and grow in the European & African feed and pet food market • Synergy to grow the product lines of Vitafor with the existing customers Key Rationale • Vitafor Invest NV was founded in February 21, 2018 is a Belgian company located 20km south of the port of Antwerp. • Manufactures and trades in products catering to the animal feed industry. • Dresen Quimica SAPI De CV , Mexico has acquired 100% stake in Vitafor Invest NV, Belgium and its underlying subsidiaries/associate on June 11, 2024 • 100% stake in Target Entity for Cash Consideration of € 1 (Euro One) Acquisition Details 16 Brief Background
Page 17
Integration Chain Guethol Phenol Hydroquinone CatecholDiphenols TBHQ VanillinBHA Ascorbyl Palmitate1 Blends Specialty Ingredients Performance Chemicals Aroma Ingredients Ethyl Vanillin MEHQ Other derivatives of HQ Guaiacol Veratrole Other derivatives of Catechol like 4 TBC Performance Chemicals Manufactured In-house 1 Ascorbyl Palmitate is not a part of HQ / Catechol value -chain and is m anufactured from ascorbic acid 17
Page 18
ESG Environmen t Social Governance • Main goal by 2030 is to switch to renewable electricity for all manufacturing facilities. Currently, company is exploring different options to achieve this goal • Dedicated to sustainability and done few initiatives from reducing food waste to sourcing clean energy • Constantly seeking new ways to promote eco-friendliness • Specifically target food segments that require improved shelf life • Offer solutions for improving nutrition, health, and hygiene in livestock, resulting in enhanced Food Conversion Ratio (FCR) and overall animal performance • Supported organizations such as Akhil Bharatiya Vanavasi Kalyan Ashram, Vanvasi Kalyan Ashram, Vivekananda Rock Memorial & Vivekanada Kendra, Institute of Chemical Technology & Kalyan Ashram to improve quality of life and sustain humanity • Employee Wellness Initiatives to provides nutritionist consulting, diet planning, gym access, and frequent health monitoring to boost employee wellness • Have a Governance Board that comprises highly skilled and visionary leaders from diverse backgrounds, bringing a wealth of technical and business expertise to the table • Actively participate in brainstorming sessions with the aim of formulating comprehensive strategies and policies 18
Page 19
Name Profile Name Profile Ashish Dandekar Chairman & Managing Director › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing › Holds a BA in Economics and Management studies from Temple University, USA Amol Shah Independent Director › Managing Director of the MJ Group with over three decades of experience covering human healthcare, F&F compounds, plant protection, and water treatment chemicals › Holds an MBA from the University of Southern California and a Bachelor’s in Engineering from the University of Kent Nirmal Momaya Managing Director › Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy › He has been instrumental in providing strategic guidance & direction to the company on all significant business matters Mahabaleshwar Palekar Independent Director › Over three decades of experience with corporates in India and MNCs › Chemical engineer with a degree from the Institute of Chemical Technology (ICT) in Mumbai, India Arjun Dukane Executive Director- Technical › Chemical Engineer with over three decades of experience in the chemical industry › Has been associated with CFS for more than 15 years Joseph Conrad D’souza Independent Director › Erstwhile Member of Executive Management and Ex-Chief Investor Relations Officer of HDFC Ltd › Holds an M.com from Mumbai University and an MBA from South Gujarat University Harsha Raghavan Non-Executive Non-Independent Director › Managing Partner of Convergent Finance LLP and ex- founding MD & CEO of Fairbridge Capital (a Fairfax Company) › Holds an MBA & MSc in industrial engineering from Stanford University and a B.A from University of California, Berkeley Pradip Kanakia Independent Director › Qualified Chartered Accountant (both England, Wales and India) with over three decades of experience › Held leadership position in PWC & KPMG, leveraging his expertise in strategy, transformation, performance management, accounting, auditing, reporting, controls, compliance & governance Anagha Dandekar Non-Executive Non-Independent Director › President & co-founder of Hardware Renaissance, a manufacturer of handcrafted door hardware and accessories › Holds an MBA in Finance from the University of South Carolina, USA Abeezar Faizullabhoy Independent Director › Senior Partner at Argus Partners (Solicitors & Advocates) – Mumbai and ex-partner of J Sagar Associates › Holds Bachelor of Law from University of Mumbai and a Solicitor from Bombay incorporated law society › Was previously on Board of CFS for 13 years till 2019, His immense experience in the Corporate commercial, litigation, M&A Jens Van Nieuwenborgh Non-Executive Non- Independent Director › Board member of several companies across India and Europe, with extensive experience in business administration, finance, and operations › Holds an MBA from Harvard University and a Master’s in Science from Ghent University, Belgium. Radhika Dudhat Non-Executive Independent Director › Over three decades of experience with corporates in India and MNCs › Partner with Shardul Amarchand Mangaldas & Co. and has worked on a wide range of transactional, regulatory and legal risk management advisory › Holds degrees in Life Sciences and Law from the University of Bombay, with postgraduate studies at Cambridge and Harvard. Board of Directors 19
Page 20
Senior Management Team Name › Profile Ashish Dandekar Chairman & Managing Director › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing › Holds a BA in Economics and Management studies from Temple University, USA Nirmal Momaya Managing Director › Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy › He has been instrumental in providing strategic guidance & direction to the company on all significant business matters Arjun Dukane Executive Director- Technical › Chemical Engineer with over three decades of experience in the chemical industry › Has been associated with CFS for more than 15 years Santosh Parab Chief Financial Officer › Over two decades of experience working auditing profession › Previously worked at B.K. Khare & Co, an Indian accounting firm › Qualified Chartered Accountant with a Bachelor’s degree in commerce › Associated with CFS for 8 years Nilesh Jadhav Chief Operating Officer › Chemical Engineer with around three decades of experience in the chemical industry including heading multilocational manufacturing sites › Previously worked at Balaji Amines, Deepak Fertilizers & Petrochemicals, Essar Refinery & Schenectady › Executive Management from IIM Bangalore and Piping Engineering from IIT Powai Eric Santos Vice President – Aroma Ingredients › Over two decades of industry experience, previously worked as a commercial director at Solvay S.A. › Holds a Bachelor’s degree in chemistry Massimo Cupello Head – Italy operations › Over three decades of experience in varied industries including food chocolate and private equity › Previously worked at Ferrero Chocolate, Unopiu (Sinergo & CCP) in Europe › Holds an MBA in International Business and a Bachelor’s degree in Science Jose Arturo Paulin Head – Mexico operations › Over two decades of experience in the feed market (premix, feed additives, pet food, and rendering) › Previously worked at Trouw Nutrition and Kemin Inc in Mexico › Qualifed agriculture engineer Jennifer Igou Head – USA operations › Over two decades of experience in food and pet-food space particularly in anti-oxidants & Hydrocolloids › Previously worked at Kemin Inc. USA & FMC › Holds a Bachelor's degree in Chemistry and Biology with an emphasis in Biomedicine 20
Page 21
Way Forward Specialty Ingredients Performance Chemicals Aroma Ingredients • Maintaining market leadership for Antioxidants • Increasing focus on high margin blends and additives. These formulations are specifically tailored to meet the diverse needs of the industry • Widen portfolio to provide a comprehensive solution for the food, pet food, biodiesel, livestock and aquaculture industries • Aim to expand Diphenol chain, specifically focusing on expanding downstream products • Introduction of new products like CME, Chloranil, Napthol etc. • Increasing manufacturing capacity of existing products through debottlenecking • Aim to give a major impetus to the 'Make in India' initiative by launching exciting products • Introduce specialized and customized products within the vanillin range, catering to diverse application needs • Actively pursuing an expansion in the aroma industry • The production of Ethyl Vanillin and vanillin ex-clove (natural vanillin) completes comprehensive range of Vanillin offerings for the market • Aim to achieve optimum capacity utilization in coming years 21
Page 22
Historical Financial Highlights
Page 23
Historical Financial Highlights Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) Net Debt to Equity (x) Net Debt to EBITDA (x) 15.3% 10.8% 12.7% 6.0% Margin9.3% 23On Consolidated Basis 0.56 0.64 0.65 0.65 0.55 FY21 FY22 FY23 FY24 FY25 2.2 3.1 3.2 5.8 3.1 FY21 FY22 FY23 FY24 FY25 11,871 14,121 16,816 FY21 FY22 FY23 14,539 1,591 FY24 16,665 263 FY25 16,131 16,928 1,819 1,528 2,131 -858 -507 FY21 FY22 FY23 1,836 FY24 2,081 FY25 978 1,574 654 604 398 530 494 FY21 FY22 FY23 -1,578 FY24 -2,075 FY25 -1,049 -1,581 Discontinued Operation Continued Operation
Page 24
Operational Revenue Break-Up Specialty Ingredients (Rs. In Mn) (Straights) Specialty Ingredients (Rs. In Mn) (Value added blends) Total Specialty Ingredients (Rs. In Mn) Aroma Ingredients (Rs. In Mn) Total Revenue Breakup (%)*Performance Chemicals (Rs. In Mn) Specialty Ingredients (Straights) Specialty Ingredients (Value Added Blends) Performance Chemicals Aroma Ingredients 24On Consolidated Basis *Excluding Other Products 2,860 3,812 4,576 4,111 3,821 FY21 FY22 FY23 FY24 FY25 3,311 4,168 5,103 7,474 8,784 FY21 FY22 FY23 FY24 FY25 6,171 7,980 9,679 11,585 12,605 FY21 FY22 FY23 FY24 FY25 1,930 135 54 347 1,758 FY21 FY22 FY23 FY24 FY25 3,444 5,865 6,881 2,412 1,956 FY21 FY22 FY23 FY24 FY25 17% 11% 30% 42% 41% 12% 29% 30% 31% 52% 54% 25% 27% 28% 29% 23% FY21 1% FY22 0% FY23 26% 2% FY24 FY25 11,545 13,980 16,614 14,344 16,319 # FY24 & FY25 figures include Diphenol CFS Europe and entire CFSWL discontinued operations
Page 25
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn) 25On Consolidated Basis 6,000 6,855 7,894 7,733 8,865 FY21 FY22 FY23 FY24 FY25 3,762 4,395 4,883 679 525 FY21 FY22 FY23 FY24 FY25 2,735 3,198 3,533 4,822 5,062 FY21 FY22 FY23 FY24 FY25 717 902 1,129 1,505 1,571 FY21 FY22 FY23 FY24 FY25 334 520 850 2,552 3,596 FY21 FY22 FY23 FY24 FY25 # FY24 & FY25 figures include Diphenol CFS Europe and entire CFSWL discontinued operations
Page 26
Thank You ! – shrikant.sangani@sgapl.net / shaily.p@sgapl.net http://www.sgapl.net/images/sgapl_logo.jpg – shrikant.sangani@sgapl.net / shaily.p@sgapl.net Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email – shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No – 9619595686 / 9819494608 www.sgapl.net http://www.sgapl.net/images/sgapl_logo.jpg santosh.parab@camlinfs.com www.camlinfs.com santosh.parab@camlinfs.com www.camlinfs.com Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – santosh.parab@camlinfs.com www.camlinfs.com